Goldman Sachs Starts Hologic (HOLX) at Buy Following Gen-Probe Deal

Article Stock Quotes (1) Comments (0)

Goldman Sachs removed their Not Rated designation on Hologic (NASDAQ: HOLX) and now rates share at Buy with a $24 price target, suggesting 22% upside.

The firm said Gen-Probe's (acquired by Hologic) assets "will accelerate top-line growth by 200bps via new product cycles and the strength of HOLX’s distribution." In addition, they are bullish on cost synergies and see upside to management guidance.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $19.65 yesterday, with a 52 week range of $13.90-$22.16.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Hologic (HOLX) Announces FDA Approval of C-View 2D Imaging for or Breast Cancer Screening
• Topeka Capital Starts Atmel (ATML) at Buy
• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold

Create E-mail Alert Related Categories

New Coverage

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?